Old Web
English
Sign In
Acemap
>
authorDetail
>
Zhe Wan
Zhe Wan
Zhejiang University
Cancer research
Hepatocellular carcinoma
Sorafenib
Medicine
Biology
7
Papers
64
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
TAK1 is a novel target in Hepatocellular Carcinoma and contributes to sorafenib resistance.
2021
Cellular and molecular gastroenterology and hepatology
Shunjie Xia
Lin Ji
Liye Tao
Yu Pan
Zhongjie Lin
Zhe Wan
Haoqi Pan
Jie Zhao
Liuxin Cai
Junjie Xu
Xiujun Cai
Show All
Source
Cite
Save
Citations (1)
UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma.
2021
Signal Transduction and Targeted Therapy
Junjie Xu
Lin Ji
Yeling Ruan
Zhe Wan
Zhongjie Lin
Shunjie Xia
Liye Tao
Junhao Zheng
Liuxin Cai
Yifan Wang
Xiao Liang
Xiujun Cai
Show All
Source
Cite
Save
Citations (12)
miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR.
2020
Cell Death and Disease
Lin Ji
Zhongjie Lin
Zhe Wan
Shunjie Xia
Shi Jiang
Dong Cen
Liuxin Cai
Junjie Xu
Xiujun Cai
Show All
Source
Cite
Save
Citations (13)
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1
2020
Signal Transduction and Targeted Therapy
Junjie Xu
Lin Ji
Yuelong Liang
Zhe Wan
Wei Zheng
Xiaomin Song
Kirill Gorshkov
Qiming Sun
Hui Lin
Xueyong Zheng
Jiang Chen
Renan Jin
Xiao Liang
Xiujun Cai
Show All
Source
Cite
Save
Citations (31)
Characterization of tumor mutation burden, PD-L1 and hepatitis B virus in Chinese hepatocellular carcinoma patients.
2019
Journal of Clinical Oncology
Junjie Xu
Xiao Liang
Lingxiang Liu
Hai-Bo Mou
Zhe Wan
Shi Jiang
Zhe Yang
Daobing Zeng
Xiaoqian Chen
Junping Shi
Ming Yao
Zhonghai Chen
Kai Wang
Show All
Source
Cite
Save
Citations (0)
1